

Necrobiosis Lipoidica - Pipeline Insight, 2021

<https://marketpublishers.com/r/N6F0911ACB70EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: N6F0911ACB70EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Necrobiosis Lipoidica - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Necrobiosis Lipoidica pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Necrobiosis Lipoidica Understanding

Necrobiosis Lipoidica: Overview

Necrobiosis lipoidica is a rare granulomatous skin disorder that usually appears in the shin area of the body and is often related to diabetes mellitus. It is an idiopathic dermatological condition. In the beginning, the lesions appear as erythematous circle papules that then evolve to well-demarcated, atrophic, shiny, yellow-brown telangiectasic multiple and bilateral plaques. The plaques develop slowly and rarely the condition ulcerates and become painful. The disease is more prevalent in females as compared to males. The exact cause of necrobiosis lipoidica is still unclear.

"Necrobiosis Lipoidica - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication.

A detailed picture of the Necrobiosis Lipoidica pipeline landscape is provided which includes the disease overview and Necrobiosis Lipoidica treatment guidelines. The assessment part of the report embraces, in depth Necrobiosis Lipoidica commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Necrobiosis Lipoidica collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Necrobiosis Lipoidica R&D. The therapies under development are focused on novel approaches to treat/improve Necrobiosis Lipoidica.

Necrobiosis Lipoidica Emerging Drugs Chapters

This segment of the Necrobiosis Lipoidica report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Necrobiosis Lipoidica Emerging Drugs

Secukinumab: Novartis

Novartis' lead drug candidate, Secukinumab is currently being evaluated for the treatment of necrobiosis lipoidica. The drug has demonstrated good efficacy in its phase I trial. It is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor thus, inhibiting the release of pro-inflammatory cytokines and chemokines.

Further product details are provided in the report.....

Necrobiosis Lipoidica: Therapeutic Assessment

This segment of the report provides insights about the different Necrobiosis Lipoidica drugs segregated based on following parameters that define the scope of the report,

such as:

Major Players in Necrobiosis Lipoidica

There are approx. 5+ key companies which are developing the therapies for Necrobiosis Lipoidica. The companies which have their Necrobiosis Lipoidica drug candidates in the most advanced stage, i.e. phase II include, Novartis.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Necrobiosis Lipoidica pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Necrobiosis Lipoidica: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Necrobiosis Lipoidica therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Necrobiosis Lipoidica drugs.

Necrobiosis Lipoidica Report Insights

Necrobiosis Lipoidica Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Necrobiosis Lipoidica Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Necrobiosis Lipoidica drugs?

How many Necrobiosis Lipoidica drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Necrobiosis Lipoidica?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Necrobiosis Lipoidica therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Necrobiosis Lipoidica and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Novartis

Processa Pharmaceuticals

Key Products

Secukinumab

PCS 499

Contents

Introduction

Executive Summary

Necrobiosis Lipoidica: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Necrobiosis Lipoidica – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Necrobiosis Lipoidica companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Necrobiosis Lipoidica Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)

Comparative Analysis

Secukinumab: Novartis

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Necrobiosis Lipoidica Key Companies

Necrobiosis Lipoidica Key Products

Necrobiosis Lipoidica- Unmet Needs

Necrobiosis Lipoidica- Market Drivers and Barriers

Necrobiosis Lipoidica- Future Perspectives and Conclusion

Necrobiosis Lipoidica Analyst Views

Necrobiosis Lipoidica Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Necrobiosis Lipoidica

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Necrobiosis Lipoidica
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Necrobiosis Lipoidica - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/N6F0911ACB70EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N6F0911ACB70EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970